LRG1 Is Involved in the Progression of Ovarian Cancer via Modulating FAK/AKT Signaling Pathway
Frontiers in Bioscience-Landmark · 2023
DOI: 10.31083/j.fbl2805101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2023. Verfasst von Dongling Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, 200092 Shanghai, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Ovarian Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Project of the Shanghai Municipal Health Commission, Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Rapid progression and early metastasis remain the main cause of high mortality in epithelial ovarian cancer (EOC) patients. The objective of this study was to explore the mechanisms of EOC progression and detect the function of leucine-rich alpha-2-glycoprotein 1 (LRG1) in modulating the pathologic process.
Methods
Ultracentrifugation was initially performed to extract exosomes from the urine samples of EOC patients and healthy female subjects. Mass spectrometry (MS) was employed to analyze differentially expressed proteins. Survival analysis was performed to examine the association between LRG1 levels and the prognosis of EOC patients. LRG1 silencing ovarian cancer cell lines were built and cell migration was further evaluated via wound healing and transwell assays. Immunoblot, immunofluorescence and immunohistochemistry analyses were performed. A subcutaneous tumor model was established to study the function of LRG1 in vivo.
Results
Exosomal LRG1 was specifically expressed in urine samples of EOC patients and high LRG1 levels were significantly associated with poor prognosis. Function analyses showed that LRG1 was associated with ovarian cancer migration and progression. Mechanistically, LRG1 was significantly related to the focal adhesion kinase/protein kinase B (FAK/AKT) signaling pathway.
Conclusions
LRG1 participated in progression and metastasis of ovarian cancer via activation of the FAK/AKT pathway probably.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, 200092 Shanghai, China.
Förderung
- Project of the Shanghai Municipal Health Commission
- Natural Science Foundation of China
Zitieren
APA
Wu, D., Xie, W., Chen, X., & Sun, H. (2023). LRG1 Is Involved in the Progression of Ovarian Cancer via Modulating FAK/AKT Signaling Pathway. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2805101
Vancouver
Wu D, Xie W, Chen X, Sun H. LRG1 Is Involved in the Progression of Ovarian Cancer via Modulating FAK/AKT Signaling Pathway. Frontiers in Bioscience-Landmark. 2023. doi:10.31083/j.fbl2805101
BibTeX
@article{Wu2023,
author = {Wu, Dongling and Xie, Weiwei and Chen, Xin and Sun, Huizhen},
title = {LRG1 Is Involved in the Progression of Ovarian Cancer via Modulating FAK/AKT Signaling Pathway},
journal = {Frontiers in Bioscience-Landmark},
year = {2023},
doi = {10.31083/j.fbl2805101}
}
EUVIMED